267 related articles for article (PubMed ID: 18095639)
1. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer.
Woloszynska-Read A; James SR; Link PA; Yu J; Odunsi K; Karpf AR
Cancer Immun; 2007 Dec; 7():21. PubMed ID: 18095639
[TBL] [Abstract][Full Text] [Related]
2. BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer.
Link PA; Zhang W; Odunsi K; Karpf AR
Cancer Immun; 2013; 13():6. PubMed ID: 23390377
[TBL] [Abstract][Full Text] [Related]
3. BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines.
Woloszynska-Read A; James SR; Song C; Jin B; Odunsi K; Karpf AR
Cancer Immun; 2010 Jul; 10():6. PubMed ID: 20649179
[TBL] [Abstract][Full Text] [Related]
4. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage.
Woloszynska-Read A; Zhang W; Yu J; Link PA; Mhawech-Fauceglia P; Collamat G; Akers SN; Ostler KR; Godley LA; Odunsi K; Karpf AR
Clin Cancer Res; 2011 Apr; 17(8):2170-80. PubMed ID: 21296871
[TBL] [Abstract][Full Text] [Related]
5. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
6. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.
Hoivik EA; Kusonmano K; Halle MK; Berg A; Wik E; Werner HM; Petersen K; Oyan AM; Kalland KH; Krakstad C; Trovik J; Widschwendter M; Salvesen HB
Oncotarget; 2014 Feb; 5(4):1052-61. PubMed ID: 24658009
[TBL] [Abstract][Full Text] [Related]
7. MAGEA1 inhibits the expression of BORIS via increased promoter methylation.
Zhao J; Wang Y; Liang Q; Xu Y; Sang J
J Cell Sci; 2019 Jan; 132(1):. PubMed ID: 30498011
[TBL] [Abstract][Full Text] [Related]
8. Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors.
Renaud S; Pugacheva EM; Delgado MD; Braunschweig R; Abdullaev Z; Loukinov D; Benhattar J; Lobanenkov V
Nucleic Acids Res; 2007; 35(21):7372-88. PubMed ID: 17962299
[TBL] [Abstract][Full Text] [Related]
9. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.
Vatolin S; Abdullaev Z; Pack SD; Flanagan PT; Custer M; Loukinov DI; Pugacheva E; Hong JA; Morse H; Schrump DS; Risinger JI; Barrett JC; Lobanenkov VV
Cancer Res; 2005 Sep; 65(17):7751-62. PubMed ID: 16140943
[TBL] [Abstract][Full Text] [Related]
10. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.
Hong JA; Kang Y; Abdullaev Z; Flanagan PT; Pack SD; Fischette MR; Adnani MT; Loukinov DI; Vatolin S; Risinger JI; Custer M; Chen GA; Zhao M; Nguyen DM; Barrett JC; Lobanenkov VV; Schrump DS
Cancer Res; 2005 Sep; 65(17):7763-74. PubMed ID: 16140944
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies.
Hoffmann MJ; Müller M; Engers R; Schulz WA
Biochem Pharmacol; 2006 Nov; 72(11):1577-88. PubMed ID: 16854382
[TBL] [Abstract][Full Text] [Related]
12. CTCFL/BORIS is a methylation-independent DNA-binding protein that preferentially binds to the paternal H19 differentially methylated region.
Nguyen P; Cui H; Bisht KS; Sun L; Patel K; Lee RS; Kugoh H; Oshimura M; Feinberg AP; Gius D
Cancer Res; 2008 Jul; 68(14):5546-51. PubMed ID: 18632606
[TBL] [Abstract][Full Text] [Related]
13. BORIS in human cancers -- a review.
Martin-Kleiner I
Eur J Cancer; 2012 Apr; 48(6):929-35. PubMed ID: 22019212
[TBL] [Abstract][Full Text] [Related]
14. DNA methyltransferase 1 and 3B activate BAG-1 expression via recruitment of CTCFL/BORIS and modulation of promoter histone methylation.
Sun L; Huang L; Nguyen P; Bisht KS; Bar-Sela G; Ho AS; Bradbury CM; Yu W; Cui H; Lee S; Trepel JB; Feinberg AP; Gius D
Cancer Res; 2008 Apr; 68(8):2726-35. PubMed ID: 18413740
[TBL] [Abstract][Full Text] [Related]
15.
Hillman JC; Pugacheva EM; Barger CJ; Sribenja S; Rosario S; Albahrani M; Truskinovsky AM; Stablewski A; Liu S; Loukinov DI; Zentner GE; Lobanenkov VV; Karpf AR; Higgins MJ
Mol Cancer Res; 2019 Oct; 17(10):2051-2062. PubMed ID: 31292201
[TBL] [Abstract][Full Text] [Related]
16. The epigenetic factor BORIS/CTCFL regulates the NOTCH3 gene expression in cancer cells.
Zampieri M; Ciccarone F; Palermo R; Cialfi S; Passananti C; Chiaretti S; Nocchia D; Talora C; Screpanti I; Caiafa P
Biochim Biophys Acta; 2014 Sep; 1839(9):813-25. PubMed ID: 24984200
[TBL] [Abstract][Full Text] [Related]
17. A polymorphic minisatellite region of BORIS regulates gene expression and its rare variants correlate with lung cancer susceptibility.
Yoon SL; Roh YG; Chu IS; Heo J; Kim SI; Chang H; Kang TH; Chung JW; Koh SS; Larionov V; Leem SH
Exp Mol Med; 2016 Jul; 48(7):e246. PubMed ID: 27416782
[TBL] [Abstract][Full Text] [Related]
18. BORIS/CTCFL expression activates the TGFβ signaling cascade and induces Drp1 mediated mitochondrial fission in neuroblastoma.
Makani VKK; Mendonza JJ; Edathara PM; Yerramsetty S; Pal Bhadra M
Free Radic Biol Med; 2021 Nov; 176():62-72. PubMed ID: 34534628
[TBL] [Abstract][Full Text] [Related]
19. [BORIS Regulates SOCS3 Expression Through Epigenetic Mechanisms in Human Hepatocellular Carcinoma Cells].
He JY; Liu QY; Wei L; Liu ZJ; Huang Y; Yu XQ; Li B; Qin Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jan; 49(1):1-7. PubMed ID: 29737080
[TBL] [Abstract][Full Text] [Related]
20. BORIS up-regulates OCT4 via histone methylation to promote cancer stem cell-like properties in human liver cancer cells.
Liu Q; Chen K; Liu Z; Huang Y; Zhao R; Wei L; Yu X; He J; Liu J; Qi J; Qin Y; Li B
Cancer Lett; 2017 Sep; 403():165-174. PubMed ID: 28645561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
